- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer
- Interventions
- iodine I 131 monoclonal antibody 81C6
- Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 347
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ABT-751
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Up to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Melanoma, Skin Cancer
- Interventions
- autologous anti-MART-1 F5 T-cell receptor, Cyclophosphamide, Fludarabine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
- Conditions
- Malignant Melanoma, Squamous Cell Carcinoma of Skin
- Interventions
- THOR-707, Cemiplimab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor
- Interventions
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Melanoma, Metastatic
- Interventions
- Pembrolizumab, FLT PET
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Interventions
- doxepin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 120
- States / cities
- Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
- Interventions
- filgrastim, allogeneic bone marrow transplantation
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Seattle, Washington
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Recombinant Interferon Alfa, Bevacizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- Lactobacillus rhamnosus GG
- Dietary Supplement
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Melanoma (Skin)
- Interventions
- everolimus
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 94
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 60 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Primary Hepatocellular Carcinoma, Adult Subependymoma, Advanced Adult Primary Liver Cancer, Advanced Malignant Mesothelioma, Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Malignant Mesothelioma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, Stage III Esophageal Cancer, Stage III Pancreatic Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Glioma, Malignant
- Interventions
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection
- Drug · Procedure
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer
- Interventions
- polymorphism analysis, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy
- Biological · Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Chondrosarcoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Nodal Marginal Zone B-cell Lymphoma, Ovarian Sarcoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Osteosarcoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Uterine Sarcoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Stage IV Uterine Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- tanespimycin, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Somatostatin Receptor Positive, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Lutetium Lu 177 Dotatate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Melanoma
- Interventions
- HF10 plus Ipilimumab
- Biological
- Lead sponsor
- Takara Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Portland, Oregon + 5 more
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
- Interventions
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Biological
- Lead sponsor
- Envita Medical Center, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
- Drug · Radiation
- Lead sponsor
- Wolfram Samlowski
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Melanoma
- Interventions
- Lenalidomide, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma, Sarcoma
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 18 Months to 40 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more